| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Kathleen McGroddy-Goetz is Director at TNDM. Kathleen McGroddy-Goetz's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $470K at current prices.
Net of sales, the TNDM filings show accumulation of 595 shares.
Kathleen McGroddy-Goetz has 13 Form 4 filings on record from June 2020 to May 2026, all as Director at Tandem Diabetes Care (TNDM), 2020–2026.
The 16 reported transactions were 8 option exercises, 6 option or other derivative awards, 1 open-market purchase and 1 open-market sale.
Counted by filing, the open-market trades come to 1 purchase worth about $21K and 1 sale worth about $43K.
The only open-market purchase was 1,000 shares of TNDM at an average $21.45 on September 15, 2023, about $21K. Twelve months later TNDM was up 102%.
The only open-market sale was 405 shares of TNDM at an average $106.00 on March 14, 2022, about $43K. Twelve months later TNDM was down 58%.